drugset / Trial / NCT00322374
Phase I Combination w/ Epirubicin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment. Tumor response assessment in evaluable participants was done according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Timeline
- Start
- 2006-08
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 25 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 35 mg/m2 | Intravenous |